NextCell Pharma AB (NXTCL.ST)
SEK 1.29
(-59.11%)
SEK 1.29
(-59.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -40.98 Million SEK | -4.12% |
| 2023 | -39.36 Million SEK | -15.48% |
| 2022 | -34.09 Million SEK | -41.35% |
| 2021 | -24.21 Million SEK | -39.58% |
| 2020 | -17.28 Million SEK | 18.11% |
| 2019 | -17.64 Million SEK | -53.78% |
| 2018 | -13.73 Million SEK | -5.97% |
| 2017 | -12.94 Million SEK | -16.48% |
| 2016 | -11.11 Million SEK | -12.56% |
| 2015 | -9.87 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -12.6 Million SEK | -44.55% |
| 2024 Q1 | -9.68 Million SEK | -13.55% |
| 2024 Q2 | -9.97 Million SEK | -3.06% |
| 2024 Q3 | -8.92 Million SEK | 12.64% |
| 2023 Q3 | -10.8 Million SEK | 4.36% |
| 2023 Q1 | -8.8 Million SEK | -4.13% |
| 2023 FY | - SEK | -15.48% |
| 2023 Q4 | -8.45 Million SEK | 21.72% |
| 2023 Q2 | -11.29 Million SEK | -28.32% |
| 2022 Q3 | -9.19 Million SEK | 8.9% |
| 2022 Q1 | -6.34 Million SEK | -46.05% |
| 2022 Q2 | -10.09 Million SEK | -58.98% |
| 2022 Q4 | -8.45 Million SEK | 8.03% |
| 2022 FY | - SEK | -41.35% |
| 2021 Q3 | -6.34 Million SEK | 21.18% |
| 2021 FY | - SEK | -39.58% |
| 2021 Q1 | -5.37 Million SEK | -12.85% |
| 2021 Q2 | -8.04 Million SEK | -49.63% |
| 2021 Q4 | -4.34 Million SEK | 31.48% |
| 2020 Q4 | -4.76 Million SEK | -1.1% |
| 2020 Q3 | -4.71 Million SEK | -13.97% |
| 2020 Q2 | -4.13 Million SEK | -12.52% |
| 2020 Q1 | -3.67 Million SEK | 49.99% |
| 2020 FY | - SEK | 18.11% |
| 2019 Q1 | -5.34 Million SEK | -60.46% |
| 2019 FY | - SEK | -53.78% |
| 2019 Q3 | -4.52 Million SEK | -30.73% |
| 2019 Q4 | -7.34 Million SEK | -62.59% |
| 2019 Q2 | -3.45 Million SEK | 35.33% |
| 2018 Q4 | -3.33 Million SEK | -10.65% |
| 2018 FY | - SEK | -5.97% |
| 2018 Q1 | -3.13 Million SEK | 33.18% |
| 2018 Q2 | -4.23 Million SEK | -35.16% |
| 2018 Q3 | -3.01 Million SEK | 28.96% |
| 2017 Q4 | -4.69 Million SEK | -32.62% |
| 2017 Q1 | -2.38 Million SEK | -4.96% |
| 2017 Q2 | -2.32 Million SEK | 2.71% |
| 2017 Q3 | -3.53 Million SEK | -52.26% |
| 2017 FY | - SEK | -16.48% |
| 2016 Q1 | -2.97 Million SEK | 0.0% |
| 2016 FY | - SEK | -12.56% |
| 2016 Q4 | -2.27 Million SEK | 21.64% |
| 2016 Q3 | -2.9 Million SEK | 2.25% |
| 2016 Q2 | -2.97 Million SEK | -0.0% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 88.857% |
| Camurus AB (publ) | 562.54 Million SEK | 107.286% |
| Mendus AB (publ) | -97.84 Million SEK | 58.113% |
| Lipum AB (publ) | -37.11 Million SEK | -10.416% |
| Simris Alg AB (publ) | -22.36 Million SEK | -83.272% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -139.897% |
| Active Biotech AB (publ) | -43.88 Million SEK | 6.612% |
| Amniotics AB (publ) | -27.14 Million SEK | -50.997% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -188.283% |
| BioArctic AB (publ) | 275.38 Million SEK | 114.883% |
| Cantargia AB (publ) | -284.31 Million SEK | 85.585% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -109.332% |
| CombiGene AB (publ) | -35.33 Million SEK | -15.987% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 70.902% |
| Genovis AB (publ.) | 64.57 Million SEK | 163.472% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 64.332% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -10.699% |
| Intervacc AB (publ) | -68.98 Million SEK | 40.584% |
| Kancera AB (publ) | -61.88 Million SEK | 33.776% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -53.027% |
| LIDDS AB (publ) | -39.67 Million SEK | -3.315% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -238.608% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 230.509% |
| OncoZenge AB (publ) | 7.26 Million SEK | 664.068% |
| Saniona AB (publ) | -69.69 Million SEK | 41.194% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 87.09% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 85.468% |
| Xintela AB (publ) | -53.47 Million SEK | 23.351% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 75.865% |
| Ziccum AB (publ) | -20.34 Million SEK | -101.48% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 2049357.6% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 82.751% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -1870.44% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -205.153% |
| Corline Biomedical AB | -1.69 Million SEK | -2323.723% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 76.353% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 25.218% |
| Aptahem AB (publ) | -10 Million SEK | -309.474% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 454.881% |
| Fluicell AB (publ) | -25.91 Million SEK | -58.158% |
| Biovica International AB (publ) | -119.5 Million SEK | 65.705% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 2.934% |
| AcouSort AB (publ) | -16.7 Million SEK | -145.376% |
| Abliva AB (publ) | -93.6 Million SEK | 56.216% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 87.156% |
| 2cureX AB (publ) | -35.13 Million SEK | -16.647% |
| I-Tech AB | 30.34 Million SEK | 235.064% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 94.264% |
| Cyxone AB (publ) | -20.41 Million SEK | -100.77% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 59.996% |
| Biosergen AB | 228 Thousand SEK | 18075.944% |
| Nanologica AB (publ) | -62.11 Million SEK | 34.022% |
| SynAct Pharma AB | -222.7 Million SEK | 81.596% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 6.557% |
| BioInvent International AB (publ) | -312.7 Million SEK | 86.893% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 13346.099% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 97686.019% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 82.305% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -365.081% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 62.246% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -257.356% |